Ten Years of Powerful Research and Results
In 2007, when Debra Black was diagnosed with Stage II melanoma, there were few treatment options. In fact, for those diagnosed with late-stage melanoma, only two FDA-Approved treatment options existed, and they only provided a 16% chance at five-year survival. After dealing with her own health concerns, she and her husband knew that they could-and needed- to do more. That’s why later that year they worked with Mike Milken to found MRA and transform the melanoma landscape.
Ten years later, we are at an unprecedented moment in the field of melanoma. Since MRA was founded, 11 new treatments have expanded the arsenal of FDA-approved treatment options and given patients and their families renewed hope. This progress is incredible, but it is only the beginning.
MRA has invested $88 million—and leveraged an additional $89.5 million—to support 233 different research projects across 15 different countries. Our research has looked at 73 unique therapeutic approaches, and has touched all 11 new treatments approved by the FDA since our founding. MRA is on the forefront of accelerating research and saving the lives of people touched by melanoma.
Read our 2016 – 2017 report to learn about the research we’ve funded, the partnerships we’ve forged, and progress we’ve made. These advancements not only improve patient outcomes, they also move us all that much closer to our goal of curing melanoma.